ISCOMATRIXTM adjuvant reduces mucosal tolerance for effective pulmonary vaccination against influenza

9Citations
Citations of this article
20Readers
Mendeley users who have this article in their library.

Abstract

While most pathogens infect via mucosal surfaces, most current vaccines are delivered by injection. This situation remains despite awareness of the potential benefits of mucosal delivery for inducing protection against mucosainfecting pathogens. A major obstacle to the development of such vaccines is the paucity of safe and effective adjuvants that induce mucosal responses in non-rodents. Previously we demonstrated in sheep the potency of pulmonary-delivered influenza ISCOMATRIXTM vaccine, which induces both mucosal and systemic immunity, even with low antigen doses. In the current study, lung pre-exposure to influenza antigen alone significantly reduced the immune response to subsequent pulmonary-delivered influenza ISCOMATRIXTM vaccine. A single dose of influenza antigen, delivered to the lung without exogenous adjuvant, upregulated IL-10 expression in bronchoalveolar lavage cells and FOXP3 expression in lung tissue, suggestive of induction of a regulatory T cell (Treg) response. However, this effect was inhibited by addition of ISCOMATRIXTM adjuvant. Moreover, effective pulmonary immunization with influenza ISCOMATRIXTM vaccine was associated with a depletion of Treg markers within lung tissues. Lung exposure to influenza antigen induced a localized mucosal tolerance that reduced the efficacy of subsequent influenza ISCOMATRIXTM vaccination. An important role of ISCOMATRIXTM adjuvant in pulmonary vaccination appears to be the depletion of Treg in lung tissues. Pulmonary vaccination remains capable of inducing a strong immune response against mucosal pathogens, but likely requires an adjuvant to overcome mucosal tolerance. ISCOMATRIXTM appears to have considerable potential as a mucosal adjuvant for use in humans, a major unmet need in mucosal vaccine development.

References Powered by Scopus

Alveolar macrophages: Plasticity in a tissue-specific context

1007Citations
N/AReaders
Get full text

Induction of secretory immunity and memory at mucosal surfaces

400Citations
N/AReaders
Get full text

Vaccination strategies for mucosal immune responses

355Citations
N/AReaders
Get full text

Cited by Powered by Scopus

Silver nanoparticle-adjuvanted vaccine protects against lethal influenza infection through inducing BALT and IgA-mediated mucosal immunity

62Citations
N/AReaders
Get full text

Nanoparticles for mucosal vaccine delivery

41Citations
N/AReaders
Get full text

Vaccine-induced antigen-specific regulatory T cells attenuate the antiviral immunity against acute influenza virus infection

40Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Timothy, A. A., Tokanovic, A., Snibson, K. J., Edwards, S. J., Pearse, M. J., Scheerlinck, J. P. Y., & Sutton, P. (2015). ISCOMATRIXTM adjuvant reduces mucosal tolerance for effective pulmonary vaccination against influenza. Human Vaccines and Immunotherapeutics, 11(2), 377–385. https://doi.org/10.4161/21645515.2014.990859

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 12

80%

Researcher 2

13%

Professor / Associate Prof. 1

7%

Readers' Discipline

Tooltip

Agricultural and Biological Sciences 5

45%

Medicine and Dentistry 3

27%

Immunology and Microbiology 2

18%

Pharmacology, Toxicology and Pharmaceut... 1

9%

Save time finding and organizing research with Mendeley

Sign up for free